UnitedHealth Goes With Praluent, Snubs Repatha
This article was originally published in Scrip
Executive Summary
Regeneron Pharmaceuticals Inc. and Sanofi SA managed to get their proprotein convertase subtilisin/kexin 9 (PCSK9) inhibitor Praluent (alirocumab) onto another big US payer's formulary – this time mega health insurer UnitedHealth Group's pharmacy benefit management (PBM) unit OptumRx.